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The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize 
procedures to assist the reasoning and decision-making of doctors.
The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending 
on the conditions and the clinical status of each patient.
introduction
Patients with intrinsic sphincter deficiency include men 
who have undergone retropubic radical prostatectomy 
(including laparoscopic or robot-assisted radical prosta-
tectomy), radical perineal prostatectomy, or transurethral 
resection of the prostate (TURP), patients with previous 
pelvic trauma or history of pelvic radiation, women who 
have undergone failed anti-incontinence procedures, and 
patients with spinal cord injury, myelomeningocele or 
other causes of neurogenic bladder, in which intrinsic 
sphincter dysfunction may also exist. Urinary incontinence 
after radical prostatectomy (UIRP) is the most common 
indication for artificial urinary sphincter (AUS) implanta-
tion.1,2 The main etiology of UIRP is sphincter deficiency 
in up to 90% of cases, either alone or combined with de-
trusor overactivity (DO).3 
The placement of the artificial urinary sphincter should 
be postponed for at least 6 months to 1 year, given that a 
portion of the patients redevelop urinary continence in 
this period. The American Medical Systems 800 (AMS 800) 
artificial urinary sphincter is the most widely-used device 
and is considered the gold standard in the treatment of 
urinary incontinence caused by intrinsic sphincter defi-
ciency, working based on hydraulic mechanics.4 The system 
consists of a cuff connected to a reservoir balloon through 
a pump. The three components are connected with torsion 
resistant tubes.5 The sizes (lengths) of the cuffs range from 
3.5 cm to 5.5 cm in 0.5 cm increments. The cuff can be 
implanted in the bulbar urethra (most common) or in the 
bladder neck. During rest, the reservoir pressure is trans-
mitted to the cuff, causing continence. Digital compression 
of the pump promotes the transfer of liquid from the cuff 
to the reservoir, relieving urethral compression and allow-
ing urination. After a period of time (3-5 minutes), the 
liquid is transferred back into the cuff by compressing the 
urethra or bladder neck, providing continence. The reser-
voir balloons come in three preset pressures: 51-60, 61-70, 
71-80 cm of water; the lowest pressure required to close 
the urethra should be used. Migration of components may 
occur if the cuff is poorly dimensioned, if the pump or 
balloon is not positioned correctly or if the pipe lengths 
are incorrect.6
The standard placement of an AUS involves a small 
incision made in the patient’s perineum or scrotum. Per-
ineal access is considered the most common;7 however, 
authors have also described the scrotal technique, thus, 
the advantages and disadvantages of each should be con-
sidered by the surgeon.8 
The “cuff,” which is the portion of the device that 
surrounds and obstructs the urethra, is usually placed 
directly around the urethra (i.e., the “standard” placement). 
Another variation for cuff placement is the transcorporal 
(TC) approach. This technique avoids the posterior ure-
thral dissection as well as of the corpora cavernosum. The 
dorsal dissection plane for cuff placement is through the 
septum of the corpora cavernosa from one side to the 
other, resulting in a portion of the ventral tunica albu-
ginea acting as a cushion between the cuff and the dorsal 
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corpus spongiosum. The transcorporal placement of the 
cuff was developed in an attempt to improve continence 
in patients with recurrent incontinence secondary to 
erosion, urethral atrophy, inadequate urethral coaptation, 
after radiotherapy, or for patients undergoing revision, 
in whom more proximal placement could not be achieved.9 
Proper patient counseling and careful attention to 
intraoperative and postoperative details are important to 
achieve good outcomes and high rates of patient satisfac-
tion. Several case series with long-term monitoring have 
demonstrated efficacy of the AUS and patient satisfaction 
even when surgical revisions are needed.10 However, im-
plantation of the AUS is an invasive procedure that can 
result in complications, such as postoperative infection, 
urethral erosion and explantation.11 Furthermore, previ-
ous urethral damage (such as failed surgical procedures, 
urethral atrophy or history of pelvic radiotherapy) may 
potentially result in technical difficulties and/or reduced 
surgical efficacy. Urinary incontinence (UI) that can occur 
after artificial urinary sphincter activation is classified as 
either early (persistent) or late onset (recurrent).12 In the 
case of persistent UI, patients never regain urinary con-
tinence following AUS activation, with urinary loss often 
similar to that experienced prior to implantation and 
during the deactivation period. Persistent incontinence 
is usually attributed to a surgical failure or inability to 
identify detrusor overactivity or any other lower urinary 
tract abnormality in the preoperative diagnostic evalua-
tion.13 On the other hand, recurrent or late-onset UI gen-
erally occurs after several months or years after the AUS 
implantation. There are several causes of persistent and/
or recurrent UI: unsuitable or accidental pump operation, 
urinary tract infection (UTI) with detrusor overactivity, 
overactive bladder, urethral atrophy, urethral erosion of 
the cuff, inadequate cuff size, insufficient pressure of the 
reservoir balloon, development (recurrence) of urethral 
or bladder neck stenosis, as well as device failure with 
fluid loss or obstruction of the control unit flow.12,14,15 
Revision rates between 8 and 45% have been reported due 
to mechanical failure, while those derived from non-
mechanical complications such as erosion, urethral atro-
phy and infections are reported between 7 and 17%.1,16-18
Certain complications have been described, with the 
most significant being erosion and/or extrusion of the 
sphincter, infection and urethral atrophy. In certain situ-
ations, there is a need to remove the device.19 The follow-
ing are risk factors for complications: pelvic radiotherapy, 
urethroplasty or any urethral manipulation and anteced-
ent erosion or infection in individuals previously submit-
ted to artificial sphincter implantation.20-22 
oBJective
The objective of our evaluation is to establish guidelines 
regarding the most important issues related to artificial 
urinary sphincter implantation: the best practices in the 
choice and preparation of the AMS 800 urinary sphinc-
ter components, preoperative care for patients with in-
dication of artificial sphincter, the best approach for 
implantation of the artificial urinary sphincter (peri-
neal or transescrotal), to compare the transcorporal 
placement of the cuff with the “standard” placement 
(directly around the urethra), regarding efficacy and 
safety, to assess the best conduct in the perioperative and 
postoperative period of artificial urinary sphincter im-
plantation, to assess the best conduct in the management 
of therapeutic failure (early or late onset urinary incon-
tinence) and to evaluate the best strategy against sus-
pected erosion or extrusion, infection and urethral at-
rophy, considering primary studies. 
Method
The initial eligibility criteria for studies were: PICO com-
ponents (Patient, Intervention, Comparison, Outcome), 
observational comparative studies (cohort and/or before-
-and-after), comparative experimental studies (clinical 
trial), absence of  restriction applied to the period of stud-
ies, no language restriction and availability of the full text. 
Medline (via PubMed), Embase, Central (Cochrane), 
Lilacs (via BVS) and manual search were the sources of 
scientific information consulted in this study.
The search strategies used Medline – (Artificial Urinary 
Sphincter OR Artificial Urinary Sphincters OR Artificial 
Genitourinary Sphincter OR Artificial Genitourinary 
Sphincters OR Artificial sphincter OR AMS 800 OR 
AMS800); other computerized databases – ‘artificial AND 
urinary AND sphincter’, and manual search – reference 
within references, revisions and guidelines. 
For study selection initially we searched by the title, 
then by the abstract, and finally by its full text, the latter 
being subject to critical evaluation and extraction of results 
related to the outcomes. 
The strength of the evidence from observational and 
experimental studies was defined taking into account the 
study design and corresponding bias risks, the results of 
the analysis (magnitude and precision), relevance and 
applicability (Oxford/GRADE).23,24 
The global evidence summary will be presented at the 
end of the results. The global evidence summary will be 
elaborated considering the evidence described.
The strength (Oxford/GRADE)23,24 will be estimated 
as 1b and 1c (grade A) or strong, and 2a, 2b and 2c (grade 
Truzzi JC eT al.
666 rev Assoc med BrAs 2017; 63(8):664-680
B) or moderate, weak or very weak. The strongest evidence 
will be considered. 
We defined seven main questions regarding male uri-
nary incontinence and artificial urinary sphincter as follows:
1. AMS 800 Model.
2. Preoperative period.
3. Perineal versus scrotal approach.
4. Transcorporal approach.
5. Perioperative and postoperative care.
6. Evaluation and conduction of therapeutic failure af-
ter AUS implantation.
7. Complications.
1. aMs 800 Model
The objective of our evaluation is to assess the best prac-
tices in the choice and preparation of the AMS 800 urinary 
sphincter components, considering primary studies. 
Clinical question
What conduct should be adopted in the choice and prep-
aration of the components of the artificial urinary sphinc-
ter model AMS 800? This question was answered in this 
evaluation using the PICO method, where P stands for 
patients with urinary incontinence due to sphincter de-
ficiency, I refers to intervention with implantation of the 
AUS model AMS 800, C is the comparison with implanta-
tion of different components and the preparation of such 
(cuff and balloon), and O is the outcome of incontinence 
control and complications. Based on the structured ques-
tion, we identified the keywords used as the basis for 
searching for evidence in the databases and after the eli-
gibility criteria (inclusion and exclusion), which were 
selected to answer the clinical question (Annex I). 
Results
In all, 1,757 studies were retrieved. Of these, 20 were se-
lected by title and eight by summary, with reading of the 
full text in the second case. After the analysis of the full 
texts, 14 studies were included in our evaluation.25-38 The 
main reasons for exclusion were: studies aiming only to 
describe the surgical technique, a series of cases with a small 
number of patients included (n < 10), and a narrative review. 
The surgeon determines the appropriate cuff size to 
be used by measuring the circumference of the tissue around 
the urethra or the bladder neck. A belt is used for cuff 
measurement, available in the device implantation kit, 
which should surround the entire urethra circumferen-
tially for proper assessment of its caliber. Additional clear-
ance is required to accommodate the patient’s urethral 
tissue between the transurethral device and the cuff. The 
thickness of the urethral tissue is patient-specific and re-
quires a surgeon’s assessment to determine its impact on 
sizing. In transcorporal implantation (TC) one must not 
undersize the cuff size, considering a size 1∕2 cm greater 
than the measured value. This is particularly true for old-
er men, since the postoperative urinary retention rate is 
significantly higher in these patients (32% [TC] vs. 8% in 
peri-urethral implantation, NNH = 4, 95CI 2-28).25 (B) 
A before-and-after study showed that the percentage 
of patients using two or more pads/day was lower in the 
larger cuff size group (5.0 to 7.0 cm) compared to patients 
with a cuff size of less than 5 cm, at a median follow-up of 
6.8 years (9.1 vs. 20.5%, NNT = NS). In addition, cuff size 
did not significantly affect the risk of complications.26 (B) 
In a historical cohort (N = 45 men), one group evalu-
ated implantation of the 3.5 cm cuff in primary and revi-
sion surgery, after repeatedly observing that loose cuffs 
led to more severe postoperative incontinence. In this 
study, compared to a larger one the 3.5 cm cuff showed 
no difference in explantation rate (9% in both groups; 
NNT = NS), due to infection and/or erosion, in an average 
follow-up of 12 months.27 (B) 
Another historical cohort (N = 59 men) evaluated the 
association of the difference between the urethral circumfer-
ence and the cuff size chosen (ΔC), in its effect on postop-
erative incontinence in a median follow-up of 4.2 years. The 
median size of the urethral cuff was 3.8 cm and 66% of the 
patients had a 4.0 cm cuff implanted. In a long-term follow-
-up, when ΔC was < 4 mm, a higher rate of urinary retention, 
erosion and atrophy was observed, and when ΔC was ≥ 4 
mm, better continence and satisfaction were observed 
(p<0.05). The results of this study suggest that a moderate 
increase in cuff size can produce better results in the long 
run. Furthermore, it demonstrated improvement in conti-
nence rates when surgeons opted for a larger cuff size when 
the urethral circumference was between two cuff sizes.28 (B) 
A historical cohort (N = 176 men) evaluated results 
comparing 100 cuff measuring 3.5 cm with 76 cuffs of 
larger sizes. Although there was no difference between 
the two groups regarding continence rates (83 vs. 80%, 
NNT = NS), patients with a history of irradiation who 
underwent 3.5 cm cuff implantation (N = 100) presented 
a 17% increase in the risk of erosion through the cuff 
(NNH = 6; 95CI 3-22).29 (B) 
The pressure-regulating balloon (PRB) determines 
the amount of pressure applied by the cuff. The surgeon 
usually implants the PRB in the pre-vesical space. A more 
recent PRB placement technique (pressure of 61-70 cm 
of H2O and filled with 24 cc saline) is high submuscular 
placement below the rectus abdominis muscle using a 
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high scrotal incision. This technique was followed for 24 
months with no difference in continence rates.30 (B) The 
surgeon usually selects the lowest balloon pressure need-
ed to maintain closure of the bulbar urethra or bladder 
neck. The most commonly used balloon pressure is 61-70 
cm / H2O (45-51 mmHg) (94% of cases worldwide). A 
pressure of 71-80 cm of H2O may be preferred in patients 
with a cuff implanted in the bladder neck.31 (D) 
The prosthesis may be filled with isotonic sterile so-
dium chloride solution or contrast, at the surgeon’s discre-
tion. The solution must be isotonic to minimize the trans-
fer of fluid through the semipermeable silicone membrane. 
Some contrast materials are hypertonic and viscous, rep-
resenting a risk of poor transmission of fluid in the device 
and transfer of fluid through the reservoir membrane. 
System pressure changes may occur over time if the balloon 
is filled with radiopaque solution at an incorrect concentra-
tion.32 (C) A history of adverse reactions to the radiopaque 
solution prevents its use as a filling medium for the pros-
thesis. If contrast solution is used, the manufacturer’s 
recommendations must be observed.6 (D) 
The filling volume of the PRB with the empty cuff 
should be 22-27 cm, depending on the size and number 
of cuffs.31 (D) 
The manufacturer’s recommendation is for the PRB 
to be filled with 22.5-23 cc of solution while the cuff is 
empty, subsequently allowing it to fill with at least 2 cc 
of solution remaining within the PRB in order to maintain 
the desired pressure range. In selected cases, intraoperative 
cuff pressurization may be considered to help determine 
the appropriate volume of total system solution.6 (D) 
The length of hospital stay will depend on the time of 
removal of the urethral catheter. A 12-Fr urethral catheter 
can be placed at the end of the procedure and left in posi-
tion overnight. Others advocate not using a catheter, al-
lowing the patient to attempt emptying after recovery from 
anesthesia. If the patient fails to do so, a new catheter is 
replaced and a further attempt at emptying it is repeated 
in 24-48 hours. In the event of persistent urinary retention 
(catheter > 48 h), a suprapubic cystostomy is preferred in 
order to reduce the risk of early erosion.32 (C) 33,34 (B) The 
“AUS Consensus Group” (2015) recommends the use of a 
≤ 14-Fr catheter and suggests removing it after a brief pe-
riod (usually overnight) if the surgery was uneventful, as 
removal on the same day may increase the risk of urinary 
retention due to pain or inflammation.31 (D) 
Several before-and-after studies show an average time 
of six weeks for activation of the system.35-38 (C) A before-
-and-after study applied a longer period of primary deacti-
vation (12 weeks) in irradiated patients. There is no evidence 
to support a primary deactivation period greater than six 
weeks. The “AUS Consensus Group” (2015) recommends 
the activation of the system between 4 and 6 weeks for 
patients undergoing the first AUS implant.31 (D) 
Global evidence summary
The choice of cuff size should be made through the precise 
measurement of the circumference of the tissue around 
the urethra or the bladder neck. When in doubt, choose 
the largest size, avoiding placement of a cuff smaller than 
the measurement of the urethral circumference. (B) 
The surgeon should select the lowest balloon pressure 
needed to maintain closure of the bulbar urethra or blad-
der neck. The most commonly used balloon pressure in 
the bulbar urethra is 61-70 cm/H2O and 71-80 cm of H2O 
may be preferred in patients with a cuff implanted in the 
bladder neck. (D) 
The prosthesis may be filled with isotonic sterile 
sodium chloride solution or contrast, at the surgeon’s 
discretion. (C) 
The filling volume of the PRB with the empty cuff 
should be 22-27 cm, depending on the size and number 
of cuffs. (D) 
The catheter left in the postoperative period can be 
≤ 14-Fr and should be removed after a brief period (usu-
ally overnight). (D) 
In the case of persistent urinary retention, the place-
ment of suprapubic cystostomy is preferable in order to 
reduce the risk of early erosion. (B) 
The AUS can be activated between 4 and 6 weeks in 
patients submitted to their first implant. (D) 
2. PreoPerative Period 
The objective of our evaluation is to suggest preoperative 
care for patients with indication of artificial urinary 
sphincter, based on primary studies. 
Clinical question
How should the preoperative evaluation be performed in 
patients who will undergo artificial urinary sphincter im-
plantation? This question was answered in our evaluation 
using the PICO method, where P stands for patients with 
moderate to severe urinary incontinence; I to intervention 
with artificial urinary sphincter; C to comparison with tak-
ing or not taking certain preoperative conduct; and O to the 
beneficial or harmful outcome in the postoperative period. 
Based on the structured question, we identified the keywords 
used as the basis for searching evidence in the databases and 
after the eligibility criteria (inclusion and exclusion), which 
were selected to answer the clinical query (Annex II). 
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Results
In total, 1,757 studies were retrieved. Of these studies, 28 
were selected by title and 20 by summary, with reading of 
the full text in the second case. After the analysis of the full 
texts, 17 studies were included in our evaluation.16,18,24,36,38-44 
The main reason for exclusion was lack of response to 
the PICO. 
The AUS should be offered to individuals with stress 
urinary incontinence (SUI) due to intrinsic sphincter 
deficiency (ISD) who have failed conservative treatment.39 
(A) Patients must have sufficient cognitive ability and 
function to operate the device.40 (D) There is a risk of 
mechanical failure of the device after five years and this 
may be related to other possible (non-mechanical) com-
plications such as infection and erosion or atrophy of the 
urethra.18 (B) The rate of reoperation for all causes is 26% 
(varying between 14.8 and 44.8%).16 (A) It is worth men-
tioning that irradiated patients may constitute a group 
with a higher risk of complications.38,41 (A) This informa-
tion must be provided to the patient. 
The pre-implantation evaluation includes a clinical 
history and, occasionally, voiding diary (urine time and 
volume, diaper use, urinary incontinence episodes), phys-
ical examination, pad test, urinalysis, and urodynamic 
evaluation.36 (B) 42 (A) 
Cystoscopy and/or urethrocystography prior to AUS 
implantation are advised when concomitant urethral ste-
nosis is suspected, which may complicate placement or put 
the AUS at risk of subsequent damage. For example, it was 
verified that up to 32% of patients presented urethrovesical 
anastomotic stenosis in the cystoscopy after radical pros-
tatectomy (RP).43 (C) Urethrovesical anastomotic stenosis 
should be stable prior to implantation. 
Sphincter deficiency can be diagnosed by urodynam-
ic examination.24 (B) Less frequently, changes in bladder 
compliance are described, as well as the occurrence of 
detrusor overactivity.44 (C) 
All sites of infection, including the urinary tract, 
should be treated prior to the procedure to protect the 
operative field from bacterial contamination. Prophylac-
tic antibiotic therapy should be administered 60 minutes 
before the incision; however, there is no standard antibi-
otic for this procedure.45 (B) 
Global evidence summary
The AUS is indicated in urinary incontinence due to in-
trinsic deficiency of the sphincter, after failure of the 
conservative treatment. (A) 
Patients should have sufficient cognitive capacity and 
function to operate the device. (D) 
They should be informed of the possible complica-
tions (mechanical or otherwise), as well as irradiated pa-
tients with greater risk. (A) 
Advise of the possibility of not remaining 100% dry. (A) 
The recommended evaluation includes a clinical his-
tory and physical examination. Urinary voiding and absor-
bent tests can be used but are not required. Urodynamics 
enables the diagnosis of sphincter deficiency. Cystoscopy 
and/or urethrocystography may be indicated in the analy-
sis of urethral stenosis or vesicourethral anastomosis when 
these changes are suspected. (A) 
All infection sites, including the urinary tract, should 
be treated prior to the procedure. (B) 
3. Perineal versus scrotal aPProach
The objective of this evaluation is to suggest the best ap-
proach for implantation of the artificial urinary sphincter, 
considering primary studies. 
Clinical question
What should be the surgical approach to artificial urinary 
sphincter implantation? This question was answered 
based on the PICO method, where P corresponds to pa-
tients with urinary incontinence due to sphincter defi-
ciency; I to intervention with implantation of an artificial 
urinary sphincter via the scrotal method; C to comparison 
with implantation via the perineal method; and O to the 
outcome in relation to control of incontinence and com-
plications. Based on the structured question, keywords 
were identified and constituted the basis of the search for 
evidence in the databases. After applying the eligibility 
criteria (inclusion and exclusion), articles were selected 
in order to answer the clinical question (Annex III). 
Results
1,757 studies were retrieved. Twenty were selected by title 
and 15 by summary, with reading of the full text in the 
second case. After the analysis of the full texts, eight stud-
ies aiming only to describe the surgical technique were 
included in our evaluation.7,8,31,46-50 Series of cases with a 
small number of patients included (n < 20) and a narrative 
review were the main reasons for exclusion.
A recent historical cohort study7 (B) including 27,096 
adult male patients compared the perineal approach (N = 
18,373) to the scrotal approach (N = 8,723) in primary 
implantation of the AUS. The perineal incision reduced 
the risk of infection by 1.0% (RRA = 1.0%, 95CI 0.006-0.014; 
NNT = 100, 95CI 72-161), as well as the risk of cuff erosion 
by 2% (RRA = 2%, 95CI 0.014-0.024; NNT = 53, 95CI 41-73). 
There was also a reduction in the risk of explantation of 
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5.7% (ARR = 5.7%, 95CI 0.048-0.066; NNT = 18, 95CI 15-21) 
and risk of revision of 2% (ARR = 2%, 95CI 0.12-0.028; NNT 
= 50, 95CI 36-83). There was no difference between the 
groups regarding the risk of atrophy.8 (C) 
Another historical cohort46 (B) included data from 
84 patients with stress urinary incontinence after prostate 
surgery, monitored for an average of 39.7 months and 
submitted to AUS implantation (5% primary). In a sub-
group analysis, perineal access (N = 24) compared to scro-
tal access (N = 60) reduced the risk of erosion by 20% (ARR 
= 20%, 95CI 0.099-0.301; NNT = 5, 95CI 3-10). There were 
no significant differences between the groups in the num-
ber of irradiated and/or anticoagulated patients, nor in 
the number of patients submitted to double-cuff place-
ment (p=0.44, 0.22 and 0.76, respectively).46 (B) Also, a 
recent historical cohort47 (B) compared perineal (N = 152) 
and penoscrotal access (N = 99) in the single cuff implan-
tation. The comparison of the two groups showed that 
the perineal route reduced the risk of explantation by 10.6%, 
in the 6-month follow-up (RRA = 10.6%, 95CI 0.017-0.195; 
NNT = 9, 95CI 5-61).47 (B)
A historical cohort study compared the scrotal to the 
perineal approach in a total of 126 artificial urinary sphinc-
ter cuffs (120 procedures, including double cuff placement 
in six), implanted in 94 patients, 63 of which were placed via 
the penoscrotal approach and 63 via the perineal approach.
In the subgroup analysis with patients undergoing a 
primary or revision procedure with a single cuff, the num-
ber of patients “completely dry” (without using pads) was 
higher in the “perineal” group (ARA = 28%, 95CI -0.48 to 
-0.07; NNH = 4, 95CI 2-14). Furthermore, perineal access 
also showed a greater number of “completely dry” patients 
(ARA = 28.7, 95CI -0.53 to -0.03; NNH = 3, 95CI 2-27). 
The number of patients in the trans-scrotal group and in 
the perineal group who required double cuff implantation 
due to incontinence was 18 and 3%, respectively (p=0.6, 
without statistical significance).48 (B)
A before-and-after study (N = 30)8 (C) reported excel-
lent results with an improved technique using a single 
scrotal incision, allowing a more proximal placement of 
the cuff and the attainment of a continence rate similar 
to those obtained with the perineal approach found in 
the literature.8 (C)
Another before-and-after study31 (C) evaluated 83 
highrisk patients (69% prostatectomy only and 31% with 
radiotherapy and/or cryotherapy) who underwent AUS 
implantation with a single transverse scrotal incision. In an 
average follow-up of 18.8 (14.6) months, the number of 
pads per day decreased from a mean of 6.7 in the preopera-
tive period to 1.1 in the postoperative period. Overall, 83% 
of the patients (79% of the irradiated ones and 85% of the 
nonirradiated ones) used ≤ 1 pad/day after surgery.49 (C)
Authors have evaluated the implantation of AUS and 
inflatable penile prosthesis simultaneously through a 
single trans-scrotal incision. They included 22 patients 
with urinary incontinence and erectile dysfunction result-
ing from radical prostatectomy in 21 patients and radical 
cystectomy in one. The average follow-up time was 17 
(12-36) months. The total revision rate was 14%, due to 
urethral erosion in two patients and migration of the 
reservoir in one. All patients reported improvement in 
urinary loss, requiring ≤ 1 pad/day. No patient suffered 
prosthesis infection in the postoperative period.50 (C)
A consensus of the International Continence Society 
(ICS) recommends that the penoscrotal approach be reserved 
for reoperation; patients with conditions that prevent place-
ment in the lithotomy position (morbid obesity, spine or 
limb deformities, neuromotor conditions); and patients who 
will undergo the AUS implantation and inflatable penile 
prosthesis through a single penoscrotal incision.31 (D)
Global evidence summary
The implantation of the AUS via the penoscrotal route can 
increase the risk of erosion, infection and explantation. (B)
The penoscrotal technique may not provide an ad-
vantage in relation to efficacy, and is associated with a 
lower continence rate than the perineal approach. (B)
The penoscrotal approach can be reserved for cases 
of reoperation; patients with conditions that impede 
placement in the lithotomy position (morbid obesity, 
spine or limb deformities, neuromotor conditions); pa-
tients who will undergo AUS implantation and inflatable 
penile prosthesis through a single penoscrotal incision; 
and patients with a previously implanted sling. (D)
The perineal approach should be the usual one. (B)
4. transcorPoral aPProach for cuff 
PlaceMent 
The aim of our evaluation is, based on primary studies, 
to compare the transcorporal placement of the cuff with 
the “standard” placement (directly around the urethra), 
regarding efficacy and safety. 
Clinical question
What is the best approach for cuff placement in artificial 
urinary sphincter implant surgery? This question was 
answered based on the PICO method, in which P stands 
for patients with moderate to severe urinary incontinence; 
I is the intervention with transcorporal cuff implantation; 
C is the comparison with “standard” cuff implantation; 
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and O stands for the outcome of control of incontinence 
and complications. Based on the structured question, 
keywords were identified and constituted the basis of the 
search for evidence in the databases. After applying the 
eligibility criteria (inclusion and exclusion), articles were 
selected in order to respond the clinical doubt (Annex IV). 
Results
In all, 1,757 studies were retrieved; ten were selected by 
title and eight by summary, with reading of the full text 
in the second case. After the analysis of the full texts, six 
studies were included in our evaluation.9,51-55 The main 
reasons for exclusion were: studies aiming only to describe 
the surgical technique, a series of cases with a small num-
ber of patients included (n < 10), and a narrative review. 
The transcorporal approach was introduced by Guralnick 
ML et al. in an effort to treat patients with previous urethral 
atrophy or erosion. In a before-and-after study, the results 
after transcorporal cuff placement were reviewed in 31 
patients with an average follow-up of 17 months. A success 
rate of 84% (26 of 31 patients) was reported, defined as 
patients with no incontinence or occasional incontinence, 
requiring 0 to 1 pad per day. In addition, 25 of 26 patients 
surveyed were very satisfied with the outcome. It is note-
worthy that seven of these patients had undergone pri-
mary double cuff placement. There were no cases of infec-
tion or erosion. Of the 31 patients, 27 had no preoperative 
erectile function, one had normal erections, one had partial 
erections with the intra-urethral drug delivery system and 
two had a penile prosthesis. Postoperative erectile function 
deteriorated in one patient and remained unchanged in 
the others.9 (C)
A historical cohort increased the original indications, 
including not only patients requiring reimplantation 
around the distal bulbar urethra, but also those submit-
ted to primary cuff placement in the proximal bulbar 
urethra, with a history of radiotherapy or with a high risk 
of erosion by the cuff due to previous urethral mobiliza-
tion for urethroplasty (N = 30; 26 with prostate cancer 
therapy). Twenty-six (26) patients were compared: 18 with 
“cuff standard setting” versus eight with “transcorporal 
approach,” after a minimum follow-up of 12 months and 
a mean follow-up of 31 and 28 months, respectively. Ap-
proximately 50% of these patients had a history of radio-
therapy. Most of the patients in the transcorporal group 
had two or more urethral surgeries prior to AUS placement, 
with a primary indication for TC prior anastomotic ure-
throplasty. Success rates for social continence (< 2 pads 
per day) were 61% using the standard approach and 87.5% 
for the transcorporal group (NNT = NS [not statistically 
significant]). AUS device explantation due to erosion or 
infection, retention (need for urethral catheter or supra-
pubic cystostomy), atrophy and incontinence were more 
common in the standard technique group. However, the 
data should be interpreted with caution (NNT = NS for 
all outcomes), since neither group is balanced. The results 
of this study showed that the TC group, despite a higher 
rate of previous urethral surgery and radiotherapy, has 
reasonable results.51 (B) 
In another study, authors evaluated data from 30 pa-
tients identified as having a “fragile urethra” post-prosta-
tectomy (pelvic irradiation, prior AUS implant failure, 
previous urethroplasty or cystoscopic and/or clinical find-
ings of urethral atrophy). Thirteen (13) of these patients 
underwent transcorporal AUS (TCAUS) and 17 had a 
“standard” approach to the cuff. Seventeen (17) patients 
had irradiation, eight had erosion and ten had previous 
urethroplasty. Five patients had multiple risk factors for 
urethral erosion. The follow-up time was 34.1 months 
(range 2-95 months) and 42.2 months (range 4-94 months) 
in the “standard” and TCAUS groups, respectively. When 
the TCAUS and “standard AUS” groups were compared, 
there was no difference in continence rates (≤ 1 pad/day) 
(NNT = NS), improvement (any reduction in the number 
of pads/day) (NNT = NS), explantation (NNT = NS) or 
erosion (NNT = NS), despite a higher proportion of previ-
ous urethroplasties in the TCAUS group.52 (B) 
The authors prospectively evaluated incontinence 
control and erectile function after prior surgical failure 
using the TC approach in AUS cuff implantation. 23 
patients with a mean age of 70 were included (age [SD], 
60-85 [7]). Of these, 18 patients had urethral atrophy and/
or erosion after AUS placement (11 patients), male sling 
(four patients) or both (three patients), and five patients 
had severe urethral atrophy after pelvic radiotherapy. 
There were no perioperative complications. After an aver-
age follow-up of 20 months (2-59 [15]) including data 
from 17 patients, eight were perfectly dry (no pads and 
no symptoms), five achieved social continence (0-1 pad/ 
day) and four still had incontinence (required two or more 
pads/day). Among the six patients who had good preop-
erative erectile function and were sexually active, four had 
no decrease in the International Index of Erectile Function 
Questionnaire (IIEF-5) score. Therefore, TC cuff place-
ment is a useful alternative after failure of prior surgical 
treatment, urethral atrophy or erosion. Erectile function 
can be maintained using the TC approach.53 (C) 
Of the 37 male patients treated with transcorporal 
AUS cuff, 20 had primary placement of transcorporal cuff, 
one of them with surgical indication due to previous 
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radiation, and 25 patients had a secondary procedure 
after failure of AUS or urinary incontinence surgery. Af-
ter a median of 32 months (minimum follow-up of two 
years), the continence rate (0 to 1 pad/day) was 69.7%. A 
total of 88% of patients reported satisfaction with the 
AUS. Patients with primary implant due to irradiation 
were no more prone to revision than non-irradiated pa-
tients. Erection preservation was reported in half of the 
potent patients.54 (C) 
A before-and-after study included 18 patients who 
had implanted AUS with dual cuff, being one or both 
cuffs placed using the TC approach. Ten patients had a 
distal cuff implanted transcorporally to complement a 
proximal bulbar urethral cuff implanted using standard 
technique. The main indication for this approach was 
erosion or infection with prior AUS. None of the patients 
had preoperative erectile function and median follow-up 
was 26 months (IQR 14-30). Results of 16 patients were 
analyzed, with continence rate (0 to 1 pad/day) at 38% 
(one completely dry). In addition, five (31%) patients 
needed 2 pads/day, and five (31%) used 3 pads/day. Before 
the implantation of the dual TC cuff, the median daily 
pad use was 5.0 (IQR 3.5-5). Complications included four 
(22%) reoperations, one erosion and two infections.55 (C) 
Global evidence summary
The TC approach for cuff implantation may be indicated 
for men with a history of urethroplasty, previous urethral 
erosion, those treated with radiotherapy, with urethral 
atrophy, and tissue involvement. (B) 
An important consideration regarding the use of a 
transcorporal approach is the erectile function of patients. 
They should be warned that this approach can lead to 
erectile dysfunction. (C)
5. PerioPerative and PostoPerative care 
The objective of this evaluation is to assess the best con-
duct in the perioperative and postoperative period of 
artificial urinary sphincter implantation, considering 
primary studies. 
Clinical question
What conduct should be adopted in the perioperative and 
postoperative period of the implantation of the artificial 
urinary sphincter in order to reduce the risks of the proce-
dure? This question was answered based on the PICO 
method, where P stands for patients with moderate to 
severe urinary incontinence, I is the intervention implanta-
tion of the AUS model AMS800® and O is the periopera-
tive and postoperative conduct that can reduce the risks 
of implantation. Based on the structured question, key-
words were identified and constituted the basis of the search 
for evidence in the databases. After applying the eligibility 
criteria (inclusion and exclusion), articles were selected in 
order to answer the clinical question (Annex V). 
Results
For this issue, 1,764 studies were retrieved, 35 were selected 
by title and 32 by summary, with reading of the full text in 
the second case. After the analysis of the full texts, 29 studies 
were included in our evaluation.1,17,26,31,34,45,56-76 Absence to 
respond to the PICO criteria was the main reason of exclusion. 
Evidence on perioperative antibiotic prophylaxis for 
urinary prosthesis placement is variable, with data ex-
trapolated from meta-analyses on hernioplasty with the 
use of mesh and orthopedic implant surgeries.45,56,57 (A) 
Thus, the adequate duration of postoperative antibiotics 
after implantation remains unknown.58 (D) 
The rate of infection in contemporary studies is be-
tween 1 and 8%57 (A) 34,59-61 (C), with rates < 2% in high-
-volume centers.1,17,62 (C) Gram-positive bacteria such as 
Staphylococcus aureus and Staphylococcus epidermidis represent 
the majority of infections, with methicillin resistance 
(MRSA) reported in 26% of the microorganisms.63 (C) 
Gram-negative infections account for 26% of infections.63 
(C) Perioperative antibiotics are routinely administered; 
however, there is no standardized antibiotic regimen, and 
the choice depends on the surgeon’s preference. It is rec-
ommended to provide both Gram-positive and Gram-
-negative coverage, including coverage for methicillin-
resistant Staphylococcus.31 (D) According to the guidelines 
of the American Urological Association on antimicrobial 
prophylaxis, this should consist of an aminoglycoside 
and a first- or second-generation cephalosporin or van-
comycin, and should be administered within 60 minutes 
before skin incision.64 (D) 
Perioperative antibiotic therapy and attention to me-
ticulous sterile techniques are the pillars of infection 
prevention. Authors have reported that a group of patients 
who rubbed the skin (five minutes rubbing the perineal 
and abdominal skin twice a day during the 5-day period 
immediately prior to AUS implantation) preoperatively 
with 4% topical chlorhexidine were four times less likely 
to suffer perineal colonization during surgery compared 
to a group receiving normal hygiene procedures (water 
and soap) [OR 0.23, p=0.003].65 (B) More recently, it has 
been demonstrated in a randomized study that alcohol 
chlorhexidine solution reduced the presence of coagulase-
-negative staphylococci at the surgical site better than 
iodopovidone (topical PVP-I).66 (A) 
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There is no evidence to support routine oral antimi-
crobial therapy postoperatively, especially in the absence 
of catheter placement and/or patient risk factors.31 (D) The 
periods of oral antibiotic therapy (quinolones, cephalospo-
rin or trimethoprim-sulfamethoxazole) in the postoperative 
period of AUS implantation vary in terms of extension, and 
are inconsistently reported in before-and-after studies.67-70 
(C) Meta-analyses of inguinal hernia repair using mesh56 
(A) and orthopedic surgery57 (A) confirm that antimicro-
bial prophylaxis is beneficial when foreign material is im-
planted. A prolonged course of antimicrobials has been 
used by many professionals after penile prosthesis insertion, 
but evidence from orthopedic literature suggests that pro-
phylaxis for 24 hours or less is adequate.71 (D) 
Trauma caused by catheterization or endoscopic ma-
nipulation in patients with an activated or malfunction-
ing device are considered as potential causes of urethral 
lesions, facilitated by tissue devascularization due to 
urethral athrophy.26,72,73 (C) Even catheters suitably placed 
for short periods can be detrimental to the long-term 
survival of the device. Authors have demonstrated a great-
er risk of erosion in patients who were catheterized for 
more than 48 hours at any time after the placement of 
the AUS.74 (C) Therefore, in situations when catheteriza-
tion is absolutely necessary, a catheter of the appropriate 
caliber should be put in place for the shortest possible 
period of time (although there is no definition of how 
many days it should remain and this varies depending on 
the clinical situation). Intermittent urinary catheterization 
is not a contraindication in the presence of an artificial 
urinary sphincter, as long as the cuff remains deflated dur-
ing the procedure.31 (D) Most patients undergoing inter-
mittent catheterization are neurogenic, so the cuff is usu-
ally placed around the neck of the bladder, reducing the 
risk of urethral erosion in comparison with positioning 
in the bulbar urethra.74 (C) 66 (D) 
The AUS must remain deactivated for six weeks. The 
first postoperative clinical visit occurs between 1-2 weeks, 
when the abdominal and perineal incisions are inspected, 
assessing the integrity of the skin and the possibility of 
infection. At the 6-week follow-up, the sphincter is acti-
vated by applying a firm and strong grip to the control 
pump, with the patient being instructed in the proper use 
of the device by the physician.75 (D) Difficulty in handling 
the pump leads to inadequate emptying of the cuff, which 
is the most common cause of postoperative urinary incon-
tinence and sphincter malfunction. In order to identify 
early complications requiring revision in the first few 
months of use, 3- and 6-month visits are the most critical, 
with subsequent frequency adjusted based on individual 
clinical circumstances. Ideally, standard follow-up should 
be conducted annually.31 (D) The immediate identification 
of infection and/or erosion facilitates intervention before 
other local or systemic consequences occur. Some surgeons 
advocate nighttime sphincter deactivation, but others 
believe that this approach is ineffective and imposes un-
necessary nighttime incontinence on the patient. A study 
comparing the two approaches demonstrated a tendency 
towards a decrease in atrophy with nocturnal deactivation, 
but the study does not have sufficient power and does not 
achieve statistical significance (ARR = 27%, 95CI -0.056 to 
0.600; NNT = NS; power = 33.57%).76 (A) 
Global evidence summary
Perioperative antibiotics are routinely administered; how-
ever, there is no standard antibiotic regimen. (D) 
It is recommended to provide both Gram-positive and 
Gram-negative coverage, including coverage for methicillin-
-resistant Staphylococcus spp. This should be administered 
within 60 minutes before cutaneous incision. (D) 
Alcohol chlorhexidine solution reduces the presence 
of coagulase-negative staphylococci at the surgical site, 
and is better than iodopovidone (topical PVP-I). (A) 
There is no evidence to support routine oral antimi-
crobial therapy postoperatively, especially in the absence 
of catheter placement and/or patient risk factors. (D) 
Trauma caused by catheterization or endoscopic ma-
nipulation in patients with an activated or malfunction-
ing device are considered as potential causes of urethral 
lesions. (C) 
In situations where catheterization is absolutely nec-
essary, it is important to place a catheter of the appropri-
ate caliber for as short a time as possible. (C)
Intermittent urinary catheterization is not a contra-
indication in the presence of an artificial urinary sphinc-
ter, provided that the cuff remains deflated during the 
procedure.66 (D) 
The first postoperative clinical visit takes place with-
in 1-2 weeks. The device should remain disabled for six 
weeks after surgery. (D) 
In order to identify early complications requiring 
revision in the first few months of use, 3- and 6-month 
visits are the most critical, with subsequent frequency 
adjusted based on individual clinical circumstances. (D) 
Standard follow-ups should be performed annually. (C) 
6. evaluation and conduction of theraPeutic 
failure after aus iMPlantation 
 The objective of this evaluation is to assess the best con-
duct in the management of therapeutic failure (early or 
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late onset urinary incontinence) after artificial urinary 
sphincter implantation, considering primary studies. 
Clinical question
What conduct should be adopted for therapeutic failure 
of urinary incontinence after implantation of the artificial 
urinary sphincter? This question was answered in this 
evaluation using the PICO method, where the P stands for 
patients with moderate to severe urinary incontinence 
presenting therapeutic failure after implantation of the 
AUS model AMS800®, I to intervention with evaluation 
and conduct during failure and O to outcomes with reso-
lution of persistent or relapsed incontinence. Based on the 
structured question, we identified the keywords used as 
the basis for searching for evidence in the databases and 
after the eligibility criteria (inclusion and exclusion), which 
were selected to answer the clinical query (Annex VI). 
Results
In all, 1,764 studies were retrieved. Of these, 30 were se-
lected by title and 26 by summary, with reading of the 
full text in the second case. After analysis of the full texts, 
24 studies were included in this evaluation.9,15,17,23,24,53,77-90 
The main reason for exclusion was that they did not re-
spond to the PICO. 
A careful clinical history and a focused physical ex-
amination guide the subsequent investigations necessary 
to determine the cause of incontinence after implantation 
of the AUS. 
Inadequate AUS operation is the most common cause 
of immediate UI post-activation. Patients should be taught 
to completely deflate the cuff and need to understand 
that emptying the bladder takes time, knowing that re-
peated recycling may be necessary. 
The control pump, if poorly placed in the scrotum, 
may also be accidentally compressed and cause involuntary 
deflation of the cuff and UI. When this happens the patient 
will complain of incontinence in certain body positions. 
The sitting position, with support directly on the urethral 
cuff, can also trigger its opening (direct compression). This 
can be solved by avoiding hard or pointed seats. 
Overactive bladder (OAB) symptoms occur in up to 
25% of post-prostatectomy patients and may be associated 
with urinary tract infection. Symptoms of de novo OAB, 
such as urgency, frequency, nocturia and urgency inconti-
nence may develop in up to 23% of patients who did not 
present these symptoms preoperatively. Those with pre-
operative OAB will have persistent symptoms in up to 71% 
of cases.91 (C) A history of urgency urinary incontinence 
prior to AUS implantation may suggest the diagnosis of 
detrusor overactivity. Whenever the pathophysiology re-
mains doubtful, urodynamic evaluation is recommended 
in order to guide treatment.31 (D) Treatment should be 
similar to that of any overactive bladder.31 (D) 
If the patient does not present continence after AUS 
activation (4-6 weeks post-implantation) in the postop-
erative period, the most common problem is a very large 
cuff or a very small reservoir. If the urethral cuff is too large, 
the coaptation of the urethra becomes insufficient, result-
ing in persistent incontinence.17 (C) The diagnosis of a cuff 
with a loose fit can be done by reviewing the surgical notes, 
urethral pressure profilometry (performed with the cuff 
in the inflated and deflated modes), urethroscopic evalu-
ation and retrograde perfusion sphincterometry with flex-
ible cystoscope.77 (C) In some cases, the reservoir balloon 
may not offer sufficient pressure for adequate urethral 
coaptation, which can be viewed cystoscopically. 
Loss of system fluids may present with persistent or 
recurrent incontinence. Fluid loss sites may include the 
urethral cuff, any area of the connecting tubing, tubing 
connections, the reservoir balloon, or rarely the control 
pump. Once the fluid has been lost from the system, the 
pumping characteristics will change until the pump is 
empty. Simple abdominal radiography may exclude fluid 
loss from the reservoir if the contrast solution is used as 
the filling medium.78 (C) If isotonic sodium chloride solu-
tion is used as a fluid medium, the radiographic evaluation 
does not help, because the silicone components are not 
radiopaque. X-rays with insufflation-deflation are necessary 
to assess the function of the sphincter. When the cuff is 
closed, a contrast ring should be visible at the cuff site. 
When the cuff is open, the pump and reservoir should con-
tain some fluid, and the cuff should have minimal fluid. If 
radiographic contrast is absent, leakage has occurred.79 (C) 
When an isotonic (sodium chloride) solution is used as the 
fluid medium, lower abdominal ultrasonography80 (C) or 
non-contrasted computed tomography (CT) of the abdo-
men and pelvis can help to assess the volume in the balloon 
and diagnose fluid loss.81 (D) However, the image will not 
help to determine the exact location of the leak. During the 
operative (revision) act, use of the electrical conductance 
test (ohmmeter) assists in identifying the defective compo-
nent and the location of the leak.81 (D) If an ohmmeter 
cannot be used to identify leakage location, the pressure in 
the reservoir can be measured by connecting the tubes to 
a pressure transducer or by aspirating and measuring the 
volume of the balloon.82 (C) Surgical exploration is required 
when fluid loss occurs. The “AUS Consensus Group” (2015) 
recommends that the entire AUS device be removed if loss 
of fluid is evident.31 (D) Nevertheless, studies have argued 
Truzzi JC eT al.
674 rev Assoc med BrAs 2017; 63(8):664-680
that in specific cases when the leakage of a component can 
be identified intraoperatively and the AUS has been placed 
for a period of < 3 years, replacement of a single component 
can be considered.83,84 (C) 
Urethral sub-cuff atrophy is defined as a progressive 
loss of initial continence after AUS implantation in the 
absence of erosion, mechanical malfunction or leakage and/
or bladder-related causes leading to worsening of urinary 
continence.31 (D) Tissue atrophy results in a loss of urethral 
compression and occlusion of the lumen. The progression 
of incontinence increases slowly over months or years and 
there is often a change in the number (increase) of pump 
activations required to open the cuff.15 (D) A simple pelvic 
X-ray will show more fluid in the cuff compared to an im-
mediate postoperative radiograph (if contrast fluid is used). 
Urethroscopy discards erosion and confirms the diagnosis 
of atrophy when poor coaptation of the mucosa at the cuff 
level is observed with it fully inflated.31 (D) Urethral with-
drawal pressure profiling can be performed with the cuff 
in inflated and deflated modes, although it is currently a 
rarely used resource. A minimal pressure change between 
the two modes suggests sub-cuff atrophy or sphincter dys-
function.15 (D) A more conservative initial therapeutic ap-
proach is preferred, such as reducing the cuff size or replac-
ing the position so that it is more proximal, whenever 
possible.17,85 (C) Other procedures such as double-cuff86-88 
(C), transcorporal (TC) cuff placement9,53,89 (C) or higher 
pressures in the reservoir may be considered. The literature 
is not clear as to the best method for cuff revision. A his-
torical cohort study showed that the placement of a “dou-
ble-cuff” was more effective than either a “smaller size” (in 
relation to mechanical failure; p=0.01) or compared to “re-
placement with a new location” (in relation to continence, 
p=0.02).90 (B) Another historical cohort compared placement 
of a double-cuff versus a single-cuff in patients with post-
-prostatectomy urinary incontinence as initial therapy. In a 
long follow-up (74-58 months), the study did not show a 
difference in the continence rate between the groups (NNT 
= NS). However, the double-cuff group had a higher number 
of complications requiring additional surgery (ARI = −0.53 
to 0.008; NNH = NS; without statistical significance).88 (B) 
Global evidence summary
Inadequate AUS operation is the most common cause of 
immediate UI post-activation. (D) 
In patients with overactive bladder and persistent UI, 
when the pathophysiology remains doubtful, a urody-
namic assessment is indicated in order to guide treatment, 
which should be similar to that of any patient with over-
active bladder. (D) 
If the patient does not show continence after AUS 
activation (4-6 weeks post-implantation) in the postop-
erative period, the most common problem is a very large 
cuff or a very small reservoir. (C) 
The diagnosis of a cuff with a loose fit can be per-
formed by reviewing the surgical notes, urodynamic study, 
urethroscopic evaluation and retrograde perfusion sphinc-
terometry with a flexible cystoscope. (C) 
Simple abdominal radiography may exclude fluid loss 
from the reservoir if the contrast solution is used as the 
filling medium. (C) 
When an isotonic (sodium chloride) solution is used 
as the fluid medium, lower abdominal ultrasonography 
(C) or non-contrasted computed tomography of the ab-
domen and pelvis can help to assess the volume in the 
balloon and diagnose fluid loss. (D) 
The “AUS Consensus Group” (2015) recommends 
that the entire AUS device be removed if a loss of fluid is 
evident. (D) 
In specific cases, when the leakage of a component 
can be identified intraoperatively and the AUS has been 
placed for a period of < 3 years, replacement of a single 
component can be considered. (C) 
Urethral sub-cuff atrophy is defined as a progressive 
loss of initial continence after AUS implantation in the 
absence of erosion, mechanical malfunction or leakage 
and/or bladder-related causes leading to worsening of 
urinary continence. (D) 
A simple pelvic X-ray will show more fluid in the cuff 
compared to an immediate postoperative radiograph (if 
contrast fluid is used). Urethroscopy can rule out erosion 
and confirm the diagnosis of atrophy when poor coapta-
tion of the mucosa at the cuff level is observed with the 
cuff fully inflated. (D) 
In atrophy, a more conservative initial therapeutic 
approach is preferred, such as reducing the cuff size or 
replacing the position to make it more proximal, when-
ever possible. (C) Other procedures such as a double-cuff 
(C), transcorporal placement of the cuff (C) or higher 
pressures in the reservoir may be considered. 
7. coMPlications 
The objective of our review is to evaluate the best strategy 
against suspected erosion or extrusion, infection and 
urethral atrophy. 
Clinical question
What is the best strategy against suspected erosion or 
extrusion and infection? This question was answered in 
this evaluation using the PICO method, where the P stands 
Male urinary incontinence: artificial sphincter
rev Assoc med BrAs 2017; 63(8):664-680 675
for the patient with urinary incontinence due to sphinc-
ter deficiency; I for intervention with an artificial urinary 
sphincter; and O for urethral erosion and infection. Based 
on the structured question, we identified the keywords 
used as the basis for searching for evidence in the data-
bases and after the eligibility criteria (inclusion and exclu-
sion), which were selected to answer the clinical question 
(Annex VII). 
Results
The usual procedure in the treatment of urethral erosion 
consists of the surgical removal of the cuff, plus passage 
of a Foley catheter or suprapubic cystostomy.19,92 (B) 
However, removal of the remaining components is not 
mandatory, as long as they are not infected. Although 
the risks and benefits of complete removal have been 
debated for a long time, acceptance of the maintenance 
of certain components has been growing.93 (C) A retro-
spective observational study that analyzed outcomes 
related to individuals submitted to the installation of 
urological prostheses in five-year period (penile prosthe-
ses installed in 300 individuals and artificial urethral 
sphincter in 251) verified that among the 120 individu-
als who required surgical re-attachment due to persistent 
urinary incontinence, erosion, urethral atrophy, mal-
functioning of the prosthesis and pain, 45% of cases (n 
= 55) did not require complete removal of all compo-
nents.94 (C) The regulatory balloon, normally placed in 
the suprapubic region, can be abandoned, provided there 
is no infection. The pump, however, is commonly re-
moved together with the cuff and connecting tubes 
between them. Another retrospective study that analyzed 
10 years of experience with artificial sphincter implanta-
tion found that 31.6% of patients (n = 25) required at 
least one additional procedure because of urethral atro-
phy (22.8%) or erosion or infection (8.9%).95 (C) In this 
analysis, two individuals submitted to the artificial 
sphincter implant were monitored clinically for several 
years even after identification of the erosion of the cuff. 
In this case, both refused surgical treatment and re-
mained continent and uninfected despite chronic erosion 
for more than five years (15 and 5 years, respectively).95 
(C) The maintenance of the cuff is an exception and is 
not supported in the literature. The usual treatment is 
removal of the eroded urethral cuff. Urethral erosion 
may result in stenosis at the affected site and require 
additional procedures to correct it. Authors have re-
ported that more than 80% of the patients presenting 
erosion followed by removal of the cuff developed ste-
nosis of the urethra.96 (C) Other authors have described 
urethroplasty at the same time as removal of the device 
to prevent subsequent stenosis.97 (C) 
With regard to infection, this may occur in the periop-
erative period or even years after implantation of the de-
vice.37 (B) Infection rates in contemporary series have been 
reported between 1 and 8%, which may be less than 2% in 
series involving a large number of patients.17,31,59,63,98 (C) 37 
(B) Gram-positive microorganisms such as Staphylococcus 
aureus and Staphylococcus epidermidis are most commonly 
associated with infection, and Gram-negative bacteria 
may be identified, such as Pseudomonas aeruginosa and 
Escherichia coli.67 (C) In the presence of superficial infection, 
oral or intravenous antibiotic treatment may be the ap-
proach of choice. However, if there is any doubt about 
the device’s impairment, it should be removed, given the 
possibility of biofilm formation on the prosthesis.67 (D) 
Global evidence summary
The recommended conduct for urethral erosion is re-
moval of the cuff and preferably of the other components. 
In selected cases, parts of the device may be retained. Do 
not remove the eroded cuff is an exception. In the pres-
ence of superficial infection, clinical treatment may ini-
tially be attempted. However, the recommended treatment 
in most cases is removal of the device, providing coverage 
for Gram-positive and Gram-negative bacteria. 
Annex I
aMs 800 Model
Clinical question
What conduct should be adopted in the choice and prep-
aration of the components of the artificial urinary sphinc-
ter model AMS 800? 
Structured question (PICO)
 • Patient – Patients with urinary incontinence due to 
sphincter deficiency. 
 • Intervention – Implantation of the AUS model AMS 800. 
 • Comparison – Different components and preparation 
of such (cuff and balloon). 
 • Outcome – Control of incontinence and complications. 
Data extraction
The results obtained from the studies included were related 
to the number of patients who obtained benefit or harm 
with different components (e.g. better cuff size) or prepara-
tion (better balloon pressure and filling liquid of the system). 
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Data analysis and expression
The results are expressed as absolute risk reduction or 
increase with their respective 95% confidence intervals. 
The number needed to treat (NNT) or number needed to 
harm (NNH) will be calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes.
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial). 
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
Annex II
PreoPerative Period
Clinical question
How should the preoperative evaluation be performed in 
patients who will undergo artificial urinary sphincter 
implantation? 
Structured question (PICO)
 • Patient – Patients with moderate to severe urinary 
incontinence. 
 • Intervention – Artificial urinary sphincter. 
 • Comparison – Taking or not taking certain preopera-
tive conducts. 
 • Outcome – Benefit or harm in the postoperative period. 
Data extraction
The results obtained from the studies included were related 
to the preoperative evaluation used and the number of pa-
tients who obtained benefits or harm from this measure. 
Data analysis and expression
Preoperative care most frequently used in the included 
studies as well as possible benefits or harm related to this 
conduct were discussed. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial). 
Annex III
Perineal versus scrotal aPProach
Clinical question
What should be the surgical approach to artificial urinary 
sphincter implantation?
Structured question (PICO)
 • Patient – Patients with urinary incontinence due to 
sphincter deficiency.
 • Intervention – Implantation of artificial urinary sphinc-
ter via the scrotal approach.
 • Comparison – Perineal implantation approach.
 • Outcome – Control of incontinence and complications.
Data extraction
The results obtained from the included studies referred 
to the number of patients who obtained benefits or harm 
from one of the two approaches. 
Data analysis and expression
The results are expressed as absolute risk reduction or 
increase with their respective 95% confidence intervals. 
The number needed to treat (NNT) or number needed to 
harm (NNH) will be calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial). 
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
Annex IV
transcorPoral aPProach
Clinical question
What is the best approach for cuff placement in artificial 
urinary sphincter implant surgery? 
Structured question (PICO)
 • Patient – Patients with moderate to severe urinary 
incontinence. 
 • Intervention – Cuff implantation using a transcorpo-
ral approach. 
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 • Comparison – “Standard” cuff implantation. 
 • Outcome – Control of incontinence and complications. 
Data extraction
The results obtained from the included studies referred 
to the number of patients who obtained benefits or harm 
from one of the two approaches. 
Data analysis and expression
The results are expressed as absolute risk reduction or 
increase with their respective 95% confidence intervals. 
The number needed to treat (NNT) or the number need-
ed to harm (NNH) will be calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial). 
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
Annex V
PerioPerative and PostoPerative care
Clinical question
What is the best approach for cuff placement in artificial 
urinary sphincter implant surgery? 
Structured question (PICO)
 • Patient – Patients with moderate to severe urinary 
incontinence. 
 • Intervention – Implantation of the AUS model AMS800. 
 • Comparison – 
 • Outcome – Perioperative and postoperative conduct 
that can reduce risks of implantation. 
Data extraction
The results obtained from the studies included were re-
lated to the number of patients who obtained benefit or 
harm with different procedures in the perioperative and 
postoperative period. 
Data analysis and expression
Whenever possible, the results will be expressed as the re-
duction or increase of the absolute risk with their respective 
95% confidence intervals and number needed to treat (NNT) 
or number needed to harm (NNH) calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial). 
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
Annex VI
evaluation and conduction of theraPeutic 
failure after aus iMPlantation
Clinical question
What conduct should be adopted for therapeutic failure 
of urinary incontinence after implantation of the artificial 
urinary sphincter? 
Structured question (PICO)
 • Patient – Patients with moderate to severe urinary in-
continence presenting therapeutic failure after implan-
tation of the AUS model AMS800®. 
 • Intervention – Assessment and conduct during failure. 
 • Comparison – 
 • Outcome – Resolution of persistent or recurrent in-
continence. 
Data extraction
The results obtained from the included studies were re-
lated to the number of patients who obtained benefits or 
damages with different procedures in the evaluation and 
conduction of the therapeutic failure after implantation 
of the AUS. 
Data analysis and expression
Whenever possible, the results will be expressed as the re-
duction or increase of the absolute risk with their respective 
95% confidence intervals and number needed to treat (NNT) 
or number needed to harm (NNH) calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
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 • It will be presented according to study design (ran-
domized controlled trial, clinical trial, before-and-af-
ter trial). 
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
Annex VII
coMPlications
Clinical question
What is the best strategy against suspected erosion or 
extrusion, infection and urethral atrophy? 
Structured question (PICO)
 • Patient – Patient with urinary incontinence due to 
sphincter deficiency. 
 • Intervention – Artificial urinary sphincter. 
 • Comparison – None. 
 • Outcome – Urethral erosion and infection. 
Data extraction
The results obtained from the included studies referred 
to the number of patients who obtained benefits or harm 
from one of the two approaches. 
Data analysis and expression
The results are expressed as absolute risk reduction or 
increase with their respective 95% confidence intervals. 
The number needed to treat (NNT) or number needed to 
harm (NNH) will be calculated. 
Description of evidence
The available evidence will follow some principles to 
be displayed: 
 • It will be shown based on benefit or harm outcomes. 
 • It will be presented according to study design (random-
ized controlled trial, clinical trial, before-and-after trial).
 • It will include the following components: number of 
patients, type of comparison, magnitude (NNT), and 
precision (95CI). 
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